Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid
Miguel Martín(Hospital General Universitario Gregorio Marañón), Ada Braun(National Cancer Centre Japan), Hugues Bourgeois(Barwon Health), Alexander Paterson, Ingo Diel, Roger Dansey(Memorial Sloan Kettering Cancer Center), Qi Jiang(National Cancer Centre Japan), Adam Brufsky(University of Pittsburgh), Alexandru Eniu(Institute of Oncology Prof. Dr. Ion Chiricuta), Yasuhiro Fujiwara(Yokohama City University), Karen Chung(Viking Therapeutics (United States)), Richard H. Bell(Geelong Hospital), Lesley Fallowfield(Brighton and Sussex Medical School), Günther Steger(Barwon Health), Charles L. Vogel(Cancer Research Institute), Diana Ritchie(Beatson West of Scotland Cancer Centre), Jacek Jassem(Gdańsk Medical University), Michelle Fan(National Cancer Centre Japan), Alison Stopeck(National Cancer Centre Japan)
Cited by 145
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k